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It is now well-established that sphingosine kinase 1 (SK1) plays a significant role in
breast cancer development, progression, and spread, whereas SK1 knockdown can
reverse these processes. In breast cancer cells and tumors, SK1 was shown to interact
with various pathways involved in cell survival and chemoresistance, such as nuclear
factor-kappa B (NFκB), Notch, Ras/MAPK, PKC, and PI3K. SK1 is upregulated by
estrogen signaling, which, in turn, confers cancer cells with resistance to tamoxifen.
Sphingosine-1-phosphate (S1P) produced by SK1 has been linked to tumor invasion
and metastasis. Both SK1 and S1P are closely linked to inflammation and adipokine
signaling in breast cancer. In human tumors, high SK1 expression has been linked with
poorer survival and prognosis. SK1 is upregulated in triple negative tumors and basal-like
subtypes. It is often associated with high phosphorylation levels of ERK1/2, SFK, LYN,
AKT, and NFκB. Higher tumor SK1 mRNA levels were correlated with poor response
to chemotherapy. This review summarizes the up-to-date evidence and discusses the
therapeutic potential for the SK1 inhibition in breast cancer, with emphasis on the
mechanisms of chemoresistance and combination with other therapies such as gefitinib
or docetaxel. We have outlined four key areas for future development, including tumor
microenvironment, combination therapies, and nanomedicine. We conclude that SK1
may have a potential as a target for precision medicine, its high expression being
a negative prognostic marker in ER-negative breast cancer, as well as a target for
chemosensitization therapy.
Keywords: sphingolipids, sphingosine kinase 1, breast cancer, progression, chemoresistance, targeted therapy,
molecular marker
BREAST CANCER-CURRENT TRENDS
Over the last 50 years, the breast cancer profile has changed enormously, with more women
surviving the disease than ever before. Since the 1970s, the incidence of female breast cancer in
Europe has increased by 72%, and it is now the most common cancer in women in the UK (1).
Despite this, mortality has fallen dramatically over the last 40 years, with the 5-year survival for
women diagnosed with breast cancer reaching 87% (1). However, it is still the second major cause
of cancer death for women in the UK, second only to lung cancer (1). Therefore, it is imperative to
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investigate the mechanisms of breast cancer progression in order
to identify new molecular targets for treatment and subsequently
new therapies.
There are many risk factors associated with the development
of breast cancer, including age, female sex, family history,
increased body mass index (BMI) (2–4), and various
reproductive factors related to lifetime levels of sex hormones,
including: early menarche; late menopause; nulliparity; hormone
replacement therapy, and lactation (which is protective against
breast cancer) (5). In addition, there are genetic factors that can
dramatically increase the risk of breast cancer, the commonest
being mutations in the DNA maintenance and repair genes,
BRCA 1/2, which confer a 60–80% risk (6).
In the UK, the NHS breast screening program offers
mammography to all women aged 47–73 (7). If patients present
with symptoms suggestive of malignancy, they are referred to
a specialist breast unit within 2 weeks to undergo a triple
assessment (clinical history and examination, imaging, and
biopsy) (8). Similarly, if a lesion is seen on imaging, such as
screening mammography, a core needle biopsy will be taken to
provide a diagnosis (9), and if indicative of breast cancer, tissue
is sent for further examination to determine hormone (estrogen
and progesterone) receptor and human epidermal growth factor
(HER2) status, as this will influence treatment decisions and
provide information regarding prognosis (10).
Breast cancer subtypes are defined using different approaches.
In the past, it was classified according to histological type and
grade, with the later addition of hormone receptor and HER2
status (11). Histologically, breast cancer can be divided into in
situ (ductal and lobular) and invasive cancer, of which there
are over 20 different types (12). The most common is invasive
ductal carcinoma, which makes up 75% of cases of breast cancer,
followed by invasive lobular carcinoma, comprising 10% of the
cases (13). Tumors are assigned one of three grades, with grade 1
being well-differentiated and grade 3 being poorly differentiated
(14, 15). Tumors are staged using the TNM (tumor, node
metastasis) system (12, 16).
As described above, after histological examination, tissue
samples are analyzed to identify the presence, or absence, of
hormone receptors (estrogen and progesterone) and HER2 status
(17). Expression of these receptors influences treatment decisions
as the presence of the estrogen receptor (ER), expressed in
∼80% of breast tumors (18), determines a tumor’s response
to endocrine therapy while expression of HER2 (19) means
that the cancer can be treated with monoclonal antibodies
that specifically target this receptor, such as trastuzumab
(herceptin) (20, 21). When all three markers are absent, the
breast cancer is described as triple negative; this constitutes
∼10–15% of breast tumors (11) and has the worst prognosis,
with a more aggressive phenotype carrying an increased risk of
recurrence (22, 23).
During the last 15 years, a classification system based on
gene expression profiling has been developed, which offers more
information about prognosis and can help to guide clinicians in
decisions regarding therapy. It was first described in 2000 (24)
and split breast cancer into four subtypes: luminal, HER2, basal-
like, and normal-like. The former has since been divided into two
(luminal A and B) (24, 25), and new categories are continually
being added, such as the claudin-low and molecular apocrine
subtypes (26–29). This mode of classification is increasingly
being used in clinical practice, with several assays now available,
the best known being Oncotype DX (30) and Mammaprint (31).
The two luminal subtypes are characterized by expression
of the ER; luminal A tumors, comprising 50–60% of breast
cancers, have low levels of expression of cell proliferation genes
(24, 32), while luminal B tumors, which make up 10–20% of
tumors, have high levels of these genes and confer a worse
prognosis (33, 34). The two can be distinguished by levels of
Ki67, a marker of cell proliferation (35). HER2 overexpressing
tumors (15–25% of breast tumors) are characterized, evidently,
by increased expression of HER2 and HER2-associated genes,
as well as genes linked to cell proliferation (36), and carry a
worse prognosis than the luminal subtypes; however, with the
advent of targeted treatment, survival has improved dramatically
(19, 20, 37, 38). Basal-like tumors are characterized by expression
of genes usually present in myoepithelial cells and are often high
grade and very aggressive, resulting in a poorer prognosis (39).
Normal-like tumors make up 5–10% of breast cancers and are
traditionally grouped together with other breast abnormalities,
such as fibroadenomas and normal breast tissue samples
(24); however, there is some debate over whether this class
truly exists, as many believe that the samples that fall into
this class simply contain high levels of normal breast tissue
(40, 41).
The treatment of breast cancer requires a multidisciplinary
approach; many therapeutic modalities are available, with the
choice of treatment depending on the presence of certainmarkers
and tumor staging (9). Generally speaking, patients with early-
stage breast cancer will be offered breast conserving surgery with
adjuvant radiotherapy, with mastectomy offered when breast
conserving surgery is not suitable or when chosen by the patient
(8), both of which have equivalent survival rates (42). Often,
medical neo-adjuvant therapy is given to patients prior to surgery
to reduce tumor size (8). Management of the axilla must also be
considered; when a diagnosis of breast cancer is made, axillary
staging is performed by ultrasound and cytology or core biopsy
(8). Whereas in the past, radical axillary clearance was the
norm, today, sentinel lymph node (SLN) biopsy is favored if the
axilla is clinically negative (43). However, the best management
for patients with a positive SLN biopsy is still unclear as
approximately half of patients who have a positive biopsy do not
have further lymph node involvement (44), and there is evidence
to suggest that axillary radiotherapy as opposed to complete
axillary clearance would be equally effective in eradicating disease
in the axilla (45, 46).
Decisions regarding post-operative adjuvant therapy are
dependent on many factors, including the tumor stage, the
grade and histological type, the expression of hormone receptors,
and the HER2 and molecular subtype (24). Patients with ER
positive cancer will be offered endocrine therapy: tamoxifen if
premenopausal and aromatase inhibitors if postmenopausal (8),
while HER2 positive tumors will be treated by biologic therapies
involving monoclonal antibodies (9). Adjuvant chemotherapy
has been shown to reduce the relative risk of death (47), but
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it is still unclear which patients will benefit. Radiotherapy,
either whole breast or partial irradiation, can be used in several
circumstances: post-lumpectomy (48); in patients with large
(>5 cm) tumors; in those with four or more positive lymph
nodes; for tumors with close margins; and for inflammatory
breast cancer (49).
For advanced breast cancer, medical therapy is the mainstay
of treatment and aims to improve survival while maintaining
a good quality of life. Choice of medical treatment depends on
hormone receptor andHER2 expression, with ER positive tumors
treated with endocrine therapy and HER2 positive tumors
treated using monoclonal antibodies. Chemotherapy is given in a
number of circumstances including breast cancer that is resistant
to hormonal therapy and hormone-receptor negative, HER2
positive, or rapidly progressive breast cancer (8). In addition to
the treatment of the primary tumor, patients will also require
therapy to control metastases, such as bisphosphonates for bone
metastases (50) or radiotherapy for brain metastases (8).
Several signaling pathways have been implicated in the
development of breast cancer; one well-known example is the
HER2 pathway, alterations in which can result in sustained
proliferation signaling and cell survival (36). The HER2 receptor
is a tyrosine kinase receptor, which, when activated, forms
dimers within the plasma membrane to activate three major
signaling pathways: Ras/Raf/MAPK, JAK/signal transducer and
activator of transcription (STAT), and PI3K/AKT/mTOR (51,
52), which control various aspects of cellular biology, including
cell growth, proliferation, division, metabolism, migration,
survival, and apoptosis.
Another pathway associated with breast cancer is the
insulin-like growth factor 1 receptor (IGFR1)/PI3K/AKT/mTOR
pathway (51, 53). There is evidence to suggest that overexpression
of IGFR1 can lead to the development of tumors and promote
formation of metastases (54). Mutations can occur at several
points along this pathway, enhancing tumor development, and
cancer cell survival; for example, PI3K mutations have been
found in up to 25% of breast cancers and up to 35% of ER-
positive cancers (55). Such mutations are thought to play a role
in resistance to treatment (52), and mutations in inhibitors of
this pathway, such as PTEN, have also been implicated in breast
cancer (56). It has been proposed that targeting the adenosine
monophosphate kinase pathway, which opposes the IGFR1
pathway (57, 58), may prove to be effective in the treatment of
breast cancer.
The pathways that regulate angiogenesis are also important
targets in the search for breast cancer treatments. One in
particular is the vascular endothelial growth factor (VEGF)
pathway, which has been the focus of much research in
recent years, as it appears to be the most important pathway
controlling angiogenesis in the first stages of cancer development.
Moreover, it has been shown that the addition of the monoclonal
antibody bevacizumab, a VEGF inhibitor, to chemotherapy
regimens in HER2 negative breast cancer and in triple
negative cancer significantly increases progression-free survival,
as well as increases overall survival in the triple negative
group (59).
SPHINGOLIPID SIGNALING IN CANCER, A
BRIEF SUMMARY
Sphingolipids are a class of lipid molecules involved in the
structure of the eukaryotic plasma membrane (60). In recent
years, they have increasingly been the focus of attention,
having emerged as cell signaling molecules and involved in
normal physiology as well as cancer cell pathophysiology
(61). Sphingolipid metabolism is complex and generates
an array of molecules; three of these molecules, namely,
ceramide, sphingosine, and sphingosine-1-phosphate (S1P), act
as signaling molecules and are involved in many biological
processes within the cell, controlling survival, proliferation,
differentiation, and apoptosis (62). Ceramide sits at the center
of sphingolipid metabolism and can be converted to the pro-
apoptotic sphingosine by ceramidase. Sphingosine can further
be metabolized to form the anti-apoptotic S1P by the action
of sphingosine kinases (SKs), of which there are two human
isoforms, SK1 and SK2. The balance between levels of ceramide
and S1P is thought to be central to determining whether a cell
survives or undergoes apoptosis (63).
The production of S1P through the action of SK1 activates
several pathways within the cell by the binding of S1P to one
of five G-protein-coupled receptors on the plasma membrane
(64). These receptors are expressed in varying levels in different
tissues, and upon the binding of S1P to its receptor, a variety of
downstream signaling cascades can be activated (65), promoting
actions including cell proliferation and migration, activation of
the inflammatory response, fibrosis, angiogenesis, nociception,
and inhibition of apoptosis. S1P may also be able to regulate
the same intracellular processes independently of a receptor (66);
several mechanisms have been proposed, including the binding
of S1P to histone deacetylases 1/2, resulting in epigenetic gene
expression (67).
In this way, SK1 also has a role in cancer progression,
facilitating many properties of cancer cells, including oncogenic
transformation (68), tumor growth (69), impairment of apoptosis
(70), tumor vascularization (71), and metastatic spread (72).
Furthermore, high SK1 levels correlate with poor prognosis and
reduced survival time in many cancers (62, 73, 74). SK1 also plays
a crucial role in resistance to cancer therapy, and targeting the
SK1/S1P pathway has been proven to be effective in the treatment
of various cancers (62, 75).
In a recent meta-analysis (74), SK1 was shown to be
significantly associated with several types of cancer, including
breast, lung, ovarian, gastric, and kidney. Significant differences
in SK1 expression were found between cancer tissues, adjacent
non-cancer tissues, and benign tissues; these results are
suggestive of a gradual increase in SK1 levels from benign to
cancerous cells. This study examined the expression of SK1
mRNA and protein in cancer cells, which demonstrated increased
levels when compared with normal cells. Finally, in terms of
survival, higher rates of SK1 expression correlated with reduced
5-year and overall survival (74).
Several studies involving knockout mice have contributed to
current thinking that SK1 can be considered as a proto-oncogene;
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for example, the size of multiple intestinal adenomas was reduced
in response to SK1 knockout (76). In addition, other studies have
shown that SK1 knockout is protective against the development
of colon cancer (77, 78), and similar results have been produced
with other cancers, such as head and neck squamous cell
carcinoma (79), lymphoma, and osteosarcomas (80).
Expression of SK1 can be upregulated through the action
of several first and second messengers, including growth
factors, cytokines, receptor tyrosine kinases, and toll-like
receptors; this process of upregulation of SK1 expression varies
depending on the type of cancer (81, 82). Release of such
cell signaling mediators stimulates the phosphorylation of SK1
by extracellular-regulated kinase (ERK1/2) (83) and protein
kinase C (PKC) (84), initiating various signaling cascades
within the cell, resulting in cell survival, and proliferation.
Additionally, SK1 expression can also be influenced by
hormones (75), an interaction shown to be true in several
types of cancer, including breast (85, 86), prostate (87), and
neuroblastoma (88).
As well as production of S1P, SK1 may have the ability
to regulate cellular processes through its interaction with
other signaling proteins (62). Some interactions, such as those
described above, increase the activity of SK1, while others
result in the upregulation of other proteins to further enhance
cell survival. Furthermore, it has been suggested that these
interactions may have an effect on the clinical outcome (89).
Additionally, increased activity of SK1 leads to decreased levels
of the pro-apoptotic molecule, sphingosine, preventing it from
switching off anti-apoptotic signaling, thus promoting cell
survival (90).
SK1 has also been touted as a potential prognostic marker
(73, 75, 91), as, in several cancers, higher SK1 levels correlate
with higher-grade tumors, reduced survival times, and faster
recurrence times. However, other reports found no correlation
between SK1 expression alone and disease outcome (92),
suggesting that either patient stratification or the mode of SK1
assessment (RNA vs. protein) may be critical for establishing
meaningful clinical correlation.
SPHINGOSINE KINASE 1 AND BREAST
CANCER
Role of SK1 in Breast Cancer
Signaling—Rationale for Targeting SK1
Sphingolipid metabolism is deregulated in cancer cells in which
SK1 and its product S1P have a critical involvement in a variety
of biological responses (93) (summarized in Figure 1). In a
comparison of five breast cancer cell lines and normal breast
epithelial cells, it was found that the triple negative breast
cancer cell line MDA-MB-231 had the highest levels of SK1
mRNA expression, protein expression, and enzyme activity. SK1
inhibition in these cells resulted in a decrease in cell proliferation
and an increase in apoptosis, an effect not seen in non-cancerous
breast epithelial cells and seen to a lesser extent in ER-positive
breast cancer cell lines (94, 95).
Triple negative breast cancer is regarded as the most
aggressive form of the disease. A recent analysis revealed that
SK1 mRNA and protein expression is higher in triple negative
breast cancer cell lines compared to non-triple negative breast
cancer cell lines (96). SK1 appears to be a critical regulator
of triple negative breast cancer metastasis. Overexpression of
SK1 in MDA-MB-231 cells in vitro increased their migration
and invasion without significant changes in proliferation (96).
Orthotopic injection of MDA-MB-231 cells overexpressing SK1
into mammary fat pads of nude mice enhanced spontaneous
lung metastasis (96). SK1 knockdown in another triple negative
breast cancer cell line (MDA-MB-435) decreased their migration
and invasion in vitro. Orthotopic injection of MDA-MB-435
with SK1 knockdown into nude mice decreased the number of
spontaneous lung metastases (96).
Ingenuity pathway analysis identified the metastasis-
promoting gene FSCN1 as a top SK1-regulated gene. SK1
upregulates the transcriptional expression of FSCN1 through
a nuclear factor-kappa B (NFκB)-mediated mechanism (96).
FSCN1 exhibited an expression pattern similar to SK1; both were
upregulated in basal subtype breast cancer compared with other
subtypes, and correlated with a poor survival rate and increased
distant metastasis in triple negative breast cancer patients (96).
In addition to metastasis and invasion, SK1 expression plays
a role in breast cancer cells’ survival. Cytotoxic effects of
doxorubicin and fluorouracil in triple negative breast cancer
cells (MDA-MB-231 and its variant LM2-4) were enhanced by
silencing of SK1 (97). Functionally, SK1 was shown to regulate
the levels of Notch signaling target gene Hes1 via S1P receptor
(S1PR) 3-mediated upregulation of Notch intracellular domain
(97). Collectively, pharmacological inhibition of SK1 appears to
be an effective therapeutic strategy for the treatment of triple
negative breast cancer (please see more details in the section SK1
Inhibition as a Therapeutic Tool—Preclinical Evidence).
S1P induces the proliferation of human ER-positive and ER-
negative breast cancer cells (98) and enhances the survival
and anchorage-independent growth of ER-positive MCF-7 cells
(99). SK1 overexpression in MCF-7 cells led to more aggressive
and larger tumors in nude mice (99) and promoted resistance
to tamoxifen, which could be restored by silencing of SK1
(100). Indeed, in ER-positive human patients, high cytoplasmic
expression of SK1 in breast tumors is associated with increased
resistance to tamoxifen, and reduced patient survival and
recurrence time (101, 102), which suggests that SK1 plays a role
in hormone resistance.
Estrogen induces SK1 expression in MCF-7 breast cancer cells
in a dose-dependent manner and produces a biphasic pattern
(85, 103, 104). The first peak is thought to be mediated by
non-genomic estrogen signaling, while the second is likely to
be due to genomic effects, secondary to the binding of estrogen
to its nuclear receptor, as evidenced by a reduction of only this
peak in response to the addition of a transcriptional inhibitor
(103). Similarly, estrogen produced a biphasic upregulation
of SK1 activity and downregulated microRNA (miR)-515-5p
in MCF-7 cells; miR-515-5p subsequently directly interacted
with SK1 3′-UTR and regulated its expression (104). A similar
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FIGURE 1 | A schematic presentation of possible signaling pathways through which SK1/S1P axis is regulated in breast cancer. SK1/S1P axis impacts breast tumor
growth, drug resistance, and metastasis (please see text for details). BMI, body mass index; DFS, disease-free survival; EGF, epidermal growth factor; EGFR, EGF
receptor; ERK, extracellular-regulated kinase; IL-6, interleukin-6; MMP-9, matrix metalloproteinase 9; OS, overall survival; S1P, sphingosine-1-phosphate; STAT3,
signal transducer and activator of transcription 3; SK, sphingosine kinase; TNF-α, tumor necrosis factor alpha.
biphasic pattern is seen when MCF-7 cells are treated with
prolactin (85). Epidermal growth factor (EGF) also has the
ability to stimulate SK1 activity within MCF-7 cells (105, 106).
Again, a biphasic response is seen (105), with the second peak
dependent on de novo protein synthesis. Treatment of cells
with EGF induces migration of SK1 to the plasma membrane,
particularly toward lamellipodia, within the first minute (106),
which enhances cell motility, growth, and apoptosis stimulated
by EGF. Various signaling pathways are involved in this process,
namely Ras/MAPK, PKC, and PI3K (105). Although several
ligands are able to upregulate the SK1 activity, it appears that only
estrogen has the ability to induce S1P export from MCF-7 breast
cancer cells (107).
There have been many studies that evaluate the link between
estrogen, SK1, S1P, and EGF receptor (EGFR). Both estrogen
and S1P have the capacity to activate EGFR (108). In MCF-
7 cells, localized measurement of EGFR levels in response to
EGF showed an EGFR decrease at the plasma membrane with
a concurrent transient increase in endosomal levels. When
stimulated by estrogen or S1P, EGFR levels at the plasma
membrane also fell but at a slower rate than when activated by
EGF, and endosomal levels increased over the time course of
the experiment (109). Downstream of the receptors, the authors
found that ERK1/2 was activated in response to all three ligands,
but with estrogen and S1P, this activation was longer and more
sustained. Similarly, activation of Cdc42 (one of the Rho GTPase
family) was also longer, meaning that the internalization and
degradation of EGFR are inhibited for longer in cells treated with
estrogen or S1P.
S1P has been closely linked to inflammation in breast cancer.
It has been shown to upregulate the expression of matrix
metalloproteinase 9 (MMP-9) (110), which has been linked to
tumor invasion and metastasis (111). Indeed, siRNA knockdown
of MMP-9 significantly reduced the invasive and migratory
phenotype of MCF-10A breast epithelial cells treated with S1P.
Additionally, Kim et al. (112) have demonstrated that binding
of S1P to S1PR3 was able to upregulate C-reactive protein
expression in MCF-10A cells in a dose-dependent fashion. This,
in turn, resulted in the activation of Rac1/ERK and PLC/Ca2+
signaling pathways, increasing MMP-9 expression, which, in
turn, stimulated breast cancer invasion and contributed to the
inflammatory environment (112).
Obesity plays a significant role in breast cancer pathogenesis.
Estrogen production by adipose tissue (both local and systemic)
is a well-established mechanism that contributes to breast cancer
incidence and prognosis, especially in postmenopausal women
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(113, 114). In addition, adipose tissue is known to produce
a wide variety of factors collectively termed adipokines, some
of which have been shown to propagate breast cancer growth
(115). Furthermore, obesity is known to induce a state of chronic
inflammation in mammary tissue, which leads to breast cancer
progression (116, 117). Sphingolipid signaling has previously
been linked with the inflammatory response (118), and S1P
serum levels positively correlate with BMI (119). In treatment-
naive breast cancer patients, S1P levels were significantly higher
in the serum of obese patients than in that of non-obese patients
(120). Breast cancer patients with higher BMI also had higher
SK1 mRNA levels in their tumors (86) and trended toward
worse overall survival and disease-free survival (119). Mice fed
with a high-fat diet had higher levels of S1P in the primary
tumor itself, in tumor interstitial fluid (representative of the
tumor microenvironment), in the systemic circulation, and in
the lungs (representative of distant sites) (120). Moreover, the
expression of SK1 and S1PR1 is higher in metastatic lesions,
along with increased levels of pro-inflammatory cytokines, such
as interleukin-6 (IL-6) and tumor necrosis factor alpha (120).
As such, the SK1/S1P/S1PR1 axis is potentially implicated in
obesity-related inflammation. FTY720 (fingolimod), a functional
antagonist of S1PRs, successfully interfered with this feed-
forward amplification loop. It was shown to reduce S1P levels
and SK1 and S1PR1 expression in the breast tumors, as well as
reduce key proinflammatory cytokines, macrophage infiltration,
and tumor progression induced by obesity (120).
Leptin is a hormone involved in appetite regulation.
Interestingly, its intratumoral levels were positively correlated
with the worse outcome in breast cancer patients. A strong
correlation between SK1 and functional leptin receptor
expression was reported in human primary breast tumors and
their associated lymph node metastases (86). The expression of
SK1 and functional leptin receptor was elevated in metastases
of ER-negative patients and showed a significant increase in
the tumors of patients with higher BMI (86). In ER-negative
breast cancer cells, SK1 knockdown significantly reduced
leptin-induced STAT3 phosphorylation. Knockdown of another
known activator of STAT3 signaling, glycoprotein (gp)130,
also resulted in a significant decrease in leptin-induced STAT3
phosphorylation. Leptin-induced STAT3 is partially cross-
activated through SK1-mediated IL-6 secretion and gp130
activation (121).
Drug resistance is an important factor implicated in the
failure of breast cancer treatment. Analysis of gene expression
in doxorubicin-treated patients showed higher expression of
SK1, S1PR1, and other genes with a known role in the
inflammatory process (such as STAT3, IL-6, and NFκB)
following treatment (119). S1P functional antagonist and
SK1 inhibitor FTY720 in combination with doxorubicin is
capable of suppressing inflammation induced by doxorubicin.
This combination inhibited growth of E0771 cells (a mouse
mammary adenocarcinoma cell line expressing the ER) in vitro
and suppressed the expression of S1P signaling-related genes,
STAT3 and IL-6, as well as reducing tumor burden in vivo
(119), suggesting that the SK1/S1P/S1PR1 axis plays a role
in doxorubicin resistance. It has been shown that in triple
negative breast cancer cell lines, MDA-MB-231 and BT-549,
mTOR inhibitor RAD001 (everolimus) reduced SK1 expression
and sensitized these cells to low-dose (5 nM) docetaxel (122).
Furthermore, in an ER-positive patient cohort, higher BMI
was positively correlated with the S1P signaling pathway but
negatively correlated with the doxorubicin-resistant gene set,
suggesting that the FTY720/doxorubicin combination may be
particularly useful for ER-positive tumors in obese patients (119).
Likewise, in triple negative breast cancer cells, FTY720 provided
chemosensitization to docetaxel following encapsulation in
nanoparticles allowing a 4-fold reduction in the effective dose and
reduced chemotherapy-induced side effects (123).
Patterns and Significance of SK1
Expression in Breast Tumors
It has been shown that in patients with breast, colon, lung,
ovarian, gastric, uterine, kidney, and rectal tumors, there is at
least a 2-fold increase in SK1 expression in cancer cells compared
with normal tissues from the same patients (124). Table 1
provides an overview of SK1 expression patterns in human breast
tumors and its clinical significance. In breast tumors, SK1 mRNA
expression was shown to increase through the four stages of
breast cancer and was associated with disease progression (93).
High levels of SK1 correlated with poorer survival and prognosis
in breast cancer patients (97). In patients with invasive ductal
carcinoma, high SK1 expression was an independent factor for
predicting shorter recurrence-free survival and was significantly
associated with more aggressive oncogenic behavior, including
higher histological grade, development of distant metastasis,
negativity for estrogen, progesterone and HER2 receptors, and
triple negativity (91). Triple negative breast cancer cells (97)
and basal-like subtypes (which often lack the ER) exhibited
the highest SK1 gene expression among the various molecular
subtypes (95–97). In a study of 65 ER-negative tumors from
patients with locally advanced or metastatic breast cancer who
were receiving doxorubicin or docetaxel-based chemotherapy,
it was shown that the tumors that failed to respond to
chemotherapy exhibited significantly higher levels of SK mRNA
compared to tumors that partially or completely responded to
treatment (95).
SK1 is a constitutively active enzyme, which can also be
phosphorylated, increasing its activity (83). Phosphorylation
of SK1 was significantly associated with higher S1P levels in
breast cancer tissue (97, 128), which correlated with lymph
node metastasis (128). High SK1 expression was associated with
a greater relative risk of development of distant metastasis
compared to the risk of pathological T and N stages (91). These
results potentially implicate SK1 as an important contributory
factor in breast cancer spread. SK1 expression is a robust
prognostic and predictive biomarker for the identification of
patients at high risk of developing distant metastasis and shorter
recurrence-free survival time (91).
SK1 expression has been demonstrated to be significantly
higher in ER-negative tumors and is associated with poorer
prognosis when compared to ER-positive tumors (95, 125). In
another study, higher SK1 expression in ER-negative tumors
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TABLE 1 | SK1 expression patterns and clinical significance in human breast tumors.
Findings mRNA/Protein
(method, sample)
Reference
Mixed cohort (n = 171 tissue samples, n = 1,098 microarray data):
– Higher SK1 expression in ER-negative tumors
– High SK1 expression in ER-positive patients insignificantly correlated with worse prognosis
mRNA (microarray,
breast tumor tissue)
(125)
ER-positive patients treated with tamoxifen (n = 304):
– High cytoplasmic SK1 expression is associated with a shorter mean time to recurrence on tamoxifen and a reduced
mean disease-specific survival time
– In ER-positive and HER1-3 positive tumors, high cytoplasmic SK1 expression is associated with an increase in the mean
disease-specific patient survival time
Protein (IHC, FFPE
tissue)
(101)
ER-positive patients treated with tamoxifen (n = 304):
– Nuclear SK1 expression is associated with shorter time to recurrence on tamoxifen and shorter disease-specific survival
– High levels of cytoplasmic SK1 and cytoplasmic ERK1/2 are associated with shorter time to recurrence on tamoxifen
– High membrane S1PR1 expression is associated with shorter time to recurrence
– High cytoplasmic S1PR3 expression is associated with shorter disease-specific survival
– Membrane and cytoplasmic S1PR3 expression correlated with PR status and nuclear S1PR3 correlated with tumor size
Protein (IHC, FFPE
tissue)
(102)
ER-negative (n = 140):
– High SK1 expression is associated with shorter disease-specific survival in HER2-positive tumors
– High cytoplasmic tumor S1PR4 is associated with shorter disease-free and disease-specific survival
– High SK1 expression in tumors with low level of S1PR4 is associated with shorter disease-free and disease-specific
survival
Protein (IHC, tissue
microarray)
(126)
ER-positive patients treated with tamoxifen (n = 304):
– High co-expression of nuclear SK1 and plasma membrane S1PR1 is associated with shorter disease-specific survival
– High levels of both nuclear SK1 and cytoplasmic S1PR3 are associated with decreased mean disease-specific survival
– High levels of either cytoplasmic or nuclear phosphorylated NFκB (p65) and nuclear SK1 correlate to shorter
disease-specific survival and recurrence times
– High expression of cytoplasmic phosphorylated c-Raf-1 or SFK or LYN or ERK1/2 or AKT and nuclear SK1 is associated
with shorter disease-specific survival and recurrence time
Protein (IHC, FFPE
tissue)
(89)
Mixed cohort (n = 112):
– Higher SK1 expression in ER-negative tumors
– Higher pathological complete response rate for tumors with high SK1 expression within the ER-positive luminal subtype
of tumors
– No correlation between HER2 status and expression of SK1
– No significant prognostic differences between tumors with high or low SK1 expression
Protein (IHC, tissue
microarray)
(127)
Mixed cohort (n = 32 tissue samples, n = 3,992 microarray data):
– Basal-like subtype had the highest SK1 gene expression among the various molecular subtypes
– SK1 expression level is inversely correlated with overall and progression-free survival
– Higher SK1 mRNA levels associated with no response to doxorubicin and docetaxel
mRNA (microarray,
tumor tissue)
(95)
Invasive ductal carcinoma (n = 224) and ductal carcinoma in situ (n = 35):
– High SK1 expression is correlated with higher histological grade, development of distant metastasis, HER2-, estrogen-,
and progesterone-negativity, and triple negativity
– Higher pathological T stage, higher pathological N stage, PR negativity, and high SK1 expression closely associate with
distant metastasis in patients with invasive ductal carcinoma
– Higher pathological T stage, lymph node and distant metastasis, advanced stage, lymphovascular invasion,
progesterone-negativity, triple negativity, and high SK1 expression predicted poor overall survival in patients with invasive
ductal carcinoma of the breast
Protein (IHC, FFPE
tissue)
(91)
Mixed cohort (n = 236):
– No significant relationship between SK1 expression alone and overall survival
– No significance was observed for high vs. low SK1 protein expression alone following stratification for HER2 or PR
– High SK1 inversely associated with both ER- and PR-positivity
Protein (IHC, FFPE
tissue)
(92)
Mixed cohort (n = 65):
– SK1 mRNA level is higher in breast cancer tissue compared to adjacent normal breast tissue
– Basal-like subtype displays the highest SK1 gene expression
– SK1 expression is higher in triple negative breast cancer patients
– High expression of SK1 is correlated with poorer survival and prognosis
– HER2-, estrogen-, and progesterone-negative tumors expressed higher SK1 mRNA
mRNA (RT-PCR, tumor
tissue)
(97)
Triple negative breast cancers (n = 117):
High expression of SK1 and FCSN1 correlated with increased distant metastasis and poor survival
Protein (IHC, FFPE
tissue)
(96)
ER, estrogen receptor; ERK, extracellular-regulated kinase; FFPE, formalin-fixed paraffin embedded; HER, human epidermal growth factor; IHC, immunohistochemistry; NFκB, nuclear
factor-kappa B; PR, progesterone receptor; RT-PCR, real-time polymerase chain reaction; SK, sphingosine kinase; S1P, sphingosine-1-phosphate; S1PR, S1P receptor.
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was also observed; however, SK1 expression did not achieve a
prognostic value for pathological complete response, which could
be due to differences in the method of analysis (IHC compared
to microarray gene expression profiling), smaller sample size of
the latter study (968 samples compared to only 112 samples),
or the fact that all patients in this study received tamoxifen
(127). In ER-negative, HER2-positive breast tumors, high SK1
expression was significantly associated with reduced disease-free
and disease-specific survival (126).
In ER-positive tumors, high cytoplasmic expression of SK1 is
associated with increased resistance to tamoxifen and reduced
patient survival and recurrence time (101, 102). Ohotski et al.
(89) have shown that localization of SK1 in the nucleus of ER-
positive tumors combined with either ERK1/2 or SFK or LYN or
AKT or NFκB profoundly reduced disease-specific survival and
recurrence times. Interestingly, not all S1PRs seem to have similar
functions in breast tumor oncogenic signaling. High expression
of S1PR1 and phosphorylated AKT or ERK1/2, as well as high
expression of cytoplasmic S1PR3 and LYN, or nuclear S1PR3
and phosphorylated Raf1, were associated with shorter disease-
specific survival time (89). By contrast, nuclear S1PR2 and c-Src
were correlated with longer disease-specific survival time and
reduced nuclear localization of SK1 (89), suggesting that S1PR2
counteracts the oncogenic action of SK1 and contributes to its
translocation (73). Patients with triple negative breast cancer
have high cytoplasmic SK1 and S1PR4 levels, which was shown
to be associated with shortened disease-specific survival and
recurrence times, as well as more advanced lymph node status,
suggesting a role for both SK1 and S1PR4 in metastasis and as
important prognostic markers in triple negative breast cancer
(73). High cytoplasmic S1PR4 levels alone confer worse disease-
free and disease-specific survival compared to tumors containing
low levels of S1PR4 (126). It was also found that patients whose
tumors contained high levels of SK1 and low levels of S1PR4 had
shorter survival times compared to those with low levels of SK1,
suggesting a functional link between the two.
Overexpression of HER2 increases SK1 expression and activity
in MCF-7 breast cancer cells. In turn, this increase in SK1
expression reduces HER2 expression in a negative feedback
manner, which limits the migration of these cells in response
to S1P (101). Stratification of ER-positive patients according
to the HER2 status showed that high cytosolic SK1 expression
was associated with increased patient survival time and reduced
recurrence rates in HER2 positive tumors (101). It was therefore
suggested that for ER/HER2-positive breast cancer patients, the
use of SK1 inhibitors might be detrimental (129). However,
another study has shown that ER-positive patients with high
SK1 and ERK1/2 expression had a shorter mean time to
recurrence of 11 years (3 vs. 14) than patients with low SK1
and ERK1/2 expression, independent of progesterone receptor
(PR), and HER2 status (102). Interestingly, in a recent study in
ER-positive breast cancer, SK1 protein expression on its own
had no correlation to overall survival or HER2/PR expression
(92), suggesting that stratification of patients and the mode of
SK1 assessment (RNA vs. protein) may be key for meaningful
clinical correlation.
SK1 Inhibition as a Therapeutic
Tool—Preclinical Evidence
The evidence suggests that targeting SK has considerable
therapeutic potential. Several inhibitors have been developed
and tested in various cancer models, including the breast
(Table 2). SK inhibitors can be broadly categorized into (a) pan-
SK inhibitors (targeting both SK1 and SK2) and (b) inhibitors
with more specificity toward a particular isozyme (we focused
on SK1 in this review). Historically, pan-SK inhibitors were
developed first (based on the sphingosine structure) followed by
more isozyme-specific inhibitors, especially after the discovery of
the SK1 structure in 2013 (135).
In JC transformed murine mammary adenocarcinoma
allografts, pan-SK inhibitors (SKI-I and SKI-II) inhibited tumor
growth without overt toxicity (132). The SK inhibitor, SKI-
II (also known as SKi), has been shown to be effective in
decreasing cell growth and survival of ER-positive MCF-7 cells
(94), as well as decreasing ER-negative breast cancer cell growth
in vitro (130). In addition, this inhibitor also decreased ERK
phosphorylation, a known downstream effect of S1P signaling,
and decreased transcriptional activity of the ER. A similar
reduction in ERK1/2 activation following treatment with SKI-
II was observed in ER-negative MDA-MB-453 breast cancer
cells (126). Moreover, SKI-II has the ability to inhibit the
actions of a tamoxifen-resistant ER, which highlights its potential
for the treatment of endocrine-resistant breast cancer (94). In
MDA-MB-468 xenograft tumors, SKI-II also demonstrated a
chemosensitization effect when combined with gefitinib (EGFR
inhibitor) (130). Similarly, combining SKI-II with paclitaxel
resulted in an additive cytotoxic effect in MDA-MB-231 cells
(131). Notably, pharmacologic inhibition of SK1 by SKI-II
in MDA-MB-231 cells increased intracellular sphingosine (an
endogenous inhibitor of PKC) levels, decreased PKC activity and
cell proliferation, and caused accumulation of cells in S phase and
SubG1 peak, indicating increased apoptosis (131).
In contrast to pan-SK inhibitors, the selective SK1 inhibitor
SK1-I does not inhibit SK2 and several other protein kinases
(136). SK1-I reduced tumor burden and metastatic growth of
4T1-luc2 tumors in mouse mammary fat pads by inducing
tumor apoptosis, reducing SK1-produced tumor S1P levels,
and reducing both tumor-induced hemangiogenesis and
lymphangiogenesis (133). SK1 expression has been positively
correlated with metastatic ability (96). Inhibition of SK1 using
the selective SK1 inhibitor PF-543 (5 and 10µM) impaired
the migration and invasion capability of MDA-MB-231 cells
in vitro and reduced the metastatic ability of MDA-MB-231
tumors in NOD/SCID mice (97). Interestingly, in head and
neck carcinoma, this inhibitor lacked the potency to induce
cancer cell apoptosis, despite a dramatic change in the cellular
S1P/sphingosine ratio (137). The authors noted that this
inhibitor did not seem to modulate cellular ceramide levels,
which might explain why it failed in inducing cell death (137).
Combining the SK1 inhibitor SK1-5C with doxorubicin and
docetaxel significantly increased the cell death of MDA-MB-
231 breast cancer cells (95). Clinically, tumors from patients
with locally advanced or metastatic ER-negative breast cancer
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TABLE 2 | Effects of SK inhibitors in breast cancer models.
Inhibitor Cell line/in vivo model Observed effect Reference
DUAL SK1/SK2 INHIBITORS (pan-SK INHIBITORS)
SKI-II MCF-7 Blocked breast cancer viability, clonogenic survival, and proliferation and decreased
estrogen signaling in vitro
(94)
SKI-II MDA-MB-468, MDA-MB-231, MDA-MB-436/
MDA-MB-468 xenograft in mice
Inhibited triple-negative breast cancer cell growth in vitro and sensitized in vivo breast
cancer xenografts to the EGFR inhibitor gefitinib
(130)
SKI-II MDA-MB-231 Increased intracellular sphingosine, decreased PKC activity and cell proliferation,
increased apoptosis
(131)
SKI-II MDA-MB-453 Reduced basal and S1P/S1PR4-induced activation of ERK1/2 and modified HER2
trafficking
(126)
SKI-I JC cell line (transformed murine mammary
adenocarcinoma) allograft in BALB/c mice
Strong inhibition of tumor growth without overt toxicity (132)
SK1-SELECTIVE INHIBITORS
SK1-I 4T1-luc2 cell line (mouse mammary
adenocarcinoma that expresses luciferase)
allograft in BALB/c mice
Reduced the size and mitotic activity of the primary tumor, lymph node, and lung
metastasis, and greatly decreased hem- and lymph-angiogenesis
Reduced S1P levels in the tumor and in circulation
(133)
PF-543 MDA-MB-231 Impaired migration and invasion capability (97)
SK1-5C MDA-MB-231, MCF-7/
MDA-MB-231 xenograft in mice
Dose-dependent induction of growth arrest, increase in apoptosis, and inhibition of
cell proliferation
Decrease in serum-secreted S1P and serum-induced phosphorylation of both
ERK1/2 and AKT in MDA-MB-231
Attenuated tumor growth in a mouse MDA-MB-231 xenograft model
(95)
SK-F MDA-MB-231/
4T1 allograft in BALB/c mice
Reduced cell proliferation
Sensitized mouse breast tumors to docetaxel
(134)
FTY720 4T1 allograft in BALB/c mice Chemosensitization to docetaxel, allowing a 4-fold reduction in the effective dose (123)
EGFR, epidermal growth factor receptor; ERK, extracellular-regulated kinase; PKC, protein kinase C; HER, human epidermal growth factor; S1P, sphingosine-1-phosphate; S1PR,
S1P receptor.
who failed to respond to doxorubicin or docetaxel-based
chemotherapy had significantly higher levels of SK1 mRNA
compared to tumors from partial or complete responders
(95). Therefore, SK1 may have a potential as a prognostic
marker in ER-negative breast cancer, as well as a target for
chemosensitizing therapy (95).
A newer generation of inhibitors have been developed
following the discovery of the SK1 crystal structure, which
identified substrate binding pockets and protein binding domains
(135). Co-crystallization of SK1 with PF-543 provided insight
into improving SK1 selectivity (138). Compound 82 (139)
[referred to as compound A (140)] was developed based on
the crystal structure of sphingosine bound to human SK1. This
compound was found to inhibit intracellular S1P production,
both human SK1 and 2 isoforms, and mouse SK1, but not mouse
SK2 (139). In contrast to docetaxel, this compound as a single
agent failed to reduce the growth of MDA-MB-231 xenograft
tumors (140), and no chemosensitization was attempted.
Similarly, we found that our selective SK1 inhibitor compound
SK-F (developed using field-template modeling) alone did not
alter the in vivo growth of 4T1 (mouse triple-negative breast
cancer cell line) cells. However, compound SK-F sensitized
mouse breast tumors to subtherapeutic doses of docetaxel (134).
Contrary to docetaxel, SK-F did not induce significant mouse
body or organ weight loss and did not have any additive toxicity
(134). The immunosuppressant FTY720 is a structural analog of
sphingosine and is phosphorylated to form FTY720-phosphate
by SK2 [reviewed in White et al. (141)]. FTY720 and (S)-FTY720
vinylphosphonate inhibit SK1 catalytic activity (142) and induce
its proteasomal degradation (143). In MCF-7 breast cancer
cells, FTY720 prevented S1P-stimulated rearrangement of actin
(144). Monotherapy with FTY720 demonstrated limited efficacy
as a single modality therapy (120), and superior efficacy was
seen when FTY720 was combined with doxorubicin (119) and
subtherapeutic doses of docetaxel (123). Therefore, reduction
of SK1 activity in cancer cells by SK1 inhibitors alone may
not be sufficient for cancer treatment. Inhibitors that merely
reversibly inhibit enzyme activity can be short acting; the
efficacy, duration of action, and induction of apoptosis by these
inhibitors may be contributory factors for this insufficiency
(144). The SK1 inhibitor/chemotherapy combination has proved
highly efficacious for overcoming chemotherapeutic resistance
and chemosensitization. When this approach is applied via
nanocarriers, a superior targeting approach withminimal toxicity
can be achieved (123).
CONCLUSIONS AND FUTURE
PERSPECTIVES
Analysis of the literature illustrates that SK1 has a clear role
in breast cancer development, progression, and spread, while
SK1 knockdown can reverse these processes. In breast cancer
cells, SK1 has been shown to interact with various pathways
involved in cell survival and chemoresistance, such as NFκB,
Notch, Ras/MAPK, PKC, and PI3K. SK1 is upregulated by
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estrogen signaling, which, in turn, confers cancer cells with
resistance to tamoxifen. S1P produced by SK1 has been shown
to upregulate the expression of MMP-9 resulting in an invasive
phenotype. Both SK1 and S1P are closely linked to inflammation
and adipokine signaling in breast cancer. In human tumors,
high SK1 expression has been linked with poorer survival and
prognosis. SK1 is upregulated in triple negative tumors and basal-
like subtypes. It is often associated with high phosphorylation
levels of ERK1/2, SFK, LYN, AKT, and NFκB and high expression
of S1PR1, 3, and 4. The relationship between SK1 and HER2 is
more complex, and careful patient stratification and/or choice of
SK1 assessment (RNA vs. protein) may be critical for meaningful
clinical correlation. Higher tumor SK1 mRNA levels were
correlated with poor response to chemotherapy.
There is ample evidence that SK1 inhibition has significant
therapeutic potential. SK1 inhibitors have been shown to reduce
breast cancer cell proliferation, clonogenic survival, migration,
and invasion. Importantly, a better outcome has been achieved in
combination with other therapies such as gefitinib or docetaxel.
Therefore, SK1 may have a potential as a target for precision
medicine, its high expression being a negative prognostic
marker in ER-negative breast cancer, as well as a target for
chemosensitizing therapy.
There are four key areas in the field of SK1/breast cancer
biology/therapy that, in our opinion, may have the greatest
potential for yielding clinically meaningful data.
1) Further assessment of the role of SK1/S1P in the tumor
microenvironment. It is well-known that the immune system
plays an enormous role in cancer detection/clearance. A
recent publication in Cell Reports (145) has outlined the
crucial role of S1P in lymphocyte differentiation frommemory
toward a regulatory (inhibitory) phenotype, suggesting that
local S1P depletion may be instrumental in re-educating the
immune system.
In breast cancer, the tumor microenvironment plays a key
role in both tumor initiation and progression. Obesity-related
chronic inflammation, secretory adipokines, and fat-derived
estrogens are all known to predispose to tumor development
and we now have evidence of the role of SK1 in these
settings (120, 133). It is possible that by targeting SK1 in these
environments, we can move further into cancer prevention
rather than treatment of late-stage cancer, when it may be
too late. Additionally, a dietary approach and the use of
natural substances as mild SK inhibitors might be considered.
A number of natural products with SK inhibitory activity
have been isolated from different sources [extensively reviewed
in (146, 147)].
2) Further identification of the exact role of SK1 expression in
disease progression. Studies looking at the expression of RNA,
protein, or phosphorylated protein showed conflicting results.
Two important issues are often overlooked in such studies:
(a) the fact that SK1 is an enzyme and it is the enzymatic
activity that in the end determines its pathophysiological
role, and (b) the exact location of measured expression—
in some studies, tumor tissue was not differentiated from
stroma and fat tissue, all of which are present in the breast
microenvironment. In addition to SK1 expression, its role in
expression/activity of other oncogenic factors may be further
explored (148, 149).
3) Clarification of the potential role of SK1 inhibitors in
cancer therapy. Initially, pan-SK inhibitors were often used
alone, and their efficacy was assessed in comparison to
chemotherapy. With the development of more selective SK1
inhibitors, it transpired that some of these compounds did
not cause cell death, while achieving good levels of SK1
inhibition (137). With the dominating hypothesis that high
SK1 levels are required for tumor development and growth,
these data puzzled researchers and prompted some to suggest
that SK1 inhibitors may have low therapeutic value. It is
possible, however, that in many tumors, high SK1 levels
confer additional proliferative/anti-apoptotic benefits, but are
not required for cell survival. If this is true, the use of SK1
inhibitors as adjuvants to chemo- or radiotherapy may be
more beneficial than their use as monotherapy.
Additionally, prolonged SK1 inhibition generates a wide
genetic response, including upregulation of multiple
prosurvival pathways as well as expression of SK2, which
provides cells with missing S1P (149). This again warrants
a trial evaluating the use of SK1 inhibitors in combination
with other molecular therapy or chemotherapy (122, 150),
or alternatively one utilizing pan-SK inhibitors, rather than
selective SK1 inhibitors.
4) Use of nanocarriers in delivering combination therapies.
There is now evidence that nanoparticle-based therapies are
advantageous due to characteristics such as targeted drug
delivery and precise kinetics of release (123, 151). Additionally,
nanocarriers may confer other properties, including imaging
capability andminimization of toxicity, when used for delivery
of combined therapies.
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